4887.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 08:15):

Stats
Dagens volum	194 900
Gjennomsnittsvolum	251 140
Markedsverdi	257.65B
EPS	¥0 ( 2024-02-13 )
Neste inntjeningsdato	( ¥59.41 ) 2024-05-08
Last Dividend	¥65.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	19.51
ATR14	¥4.73 (0.08%)

Volum Korrelasjon

Lang: -0.22 (neutral)

Kort: 0.47 (neutral)

Signal:(64.412) Neutral

Sawai Group Holdings Co., Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Sawai Group Holdings Co., Korrelasjon - Valuta/Råvare

0.80
( moderate )

0.25
( neutral )

0.26
( neutral )

0.31
( neutral )

0.02
( neutral )

-0.70
( moderate negative )

Sawai Group Holdings Co., Økonomi

Annual	2022
Omsetning:	¥200.34B
Bruttogevinst:	¥62.63B (31.26 %)
EPS:	¥289.26

FY	2022
Omsetning:	¥200.34B
Bruttogevinst:	¥62.63B (31.26 %)
EPS:	¥289.26

FY	2022
Omsetning:	¥193.82B
Bruttogevinst:	¥66.65B (34.39 %)
EPS:	¥-957.37

Financial Reports:

No articles found.

Sawai Group Holdings Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥65.00 (N/A)	¥0 (N/A)	¥65.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Sawai Group Holdings Co., Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.15 - good (91.49%) | Divividend Growth Potential Score: 3.14 - Decrease likely (37.15%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥65.00	2021-09-29
Last Dividend	¥65.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	¥260.00	--
Avg. Dividend % Per Year	0.00%	--
Score	2.89	--
Div. Sustainability Score	9.15
Div.Growth Potential Score	3.14
Div. Directional Score	6.15	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

2.89

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9404.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8068.T	Ex Dividend Knight	2024-01-30	Semi-Annually	0.00%
7350.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6590.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
5936.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4617.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3852.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3093.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
1967.T	Ex Dividend Junior	2024-03-18	Annually	0.00%
9982.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0749	1.500	8.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0392	1.200	8.69	10.00	[0 - 0.3]
returnOnEquityTTM	0.0735	1.500	-0.294	-0.441	[0.1 - 1]
payoutRatioTTM	0.372	-1.000	6.28	-6.28	[0 - 1]
currentRatioTTM	2.18	0.800	4.09	3.27	[1 - 3]
quickRatioTTM	0.782	0.800	-0.108	-0.0867	[0.8 - 2.5]
cashRatioTTM	0.254	1.500	9.70	10.00	[0.2 - 2]
debtRatioTTM	0.229	-1.500	6.19	-9.28	[0 - 0.6]
interestCoverageTTM	40.11	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	544.46	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	-35.66	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0.425	-1.500	8.30	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.305	1.000	8.25	8.25	[0.2 - 0.8]
operatingProfitMarginTTM	0.0968	1.000	-0.0640	-0.0640	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.267	1.000	9.63	9.63	[0.2 - 2]
assetTurnoverTTM	0.524	0.800	9.84	7.87	[0.5 - 2]
Total Score				9.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	16.89	1.000	8.40	0	[1 - 100]
returnOnEquityTTM	0.0735	2.50	-0.189	-0.441	[0.1 - 1.5]
freeCashFlowPerShareTTM	-35.66	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	2.20	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	544.46	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.372	1.500	6.28	-6.28	[0 - 1]
pegRatioTTM	-0.0513	1.500	-3.68	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.117	1.000	9.59	0	[0.1 - 0.5]
Total Score				3.14

Sawai Group Holdings Co.,

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.